Boston Scientific (NYSE:BSX) launched its next-generation Promus Element Plus drug-eluting stent in Canada following approval from regulators this week.
The Promus Element Plus, built on the Promus Element stent design, features a modified catheter delivery system, according to a press release.
"We are pleased to introduce the Promus Element Plus Stent System to physicians and patients in Canada," interventional cardiology president Kevin Balligner said in prepared remarks.
"It is the latest example of Boston Scientific’s commitment to market leadership and continued innovation in drug-eluting stents," he added.
BSX shares were up 0.7% to $6.09 as of about 2:15 p.m. today.
The Promus Element stent system is the med-tech titan’s platinum-chromium iteration of an everolimus-eluting stent like the original Promus, a private-label version of Abbott’s (NYSE:ABT) Xience V.
The private-label deal ended in Europe in 2009, but a similar arrangement in the U.S. is slated to go until mid-2012. Dwindling royalty payments from the Promus stents were noted in Abbott’s sliding Q1 2012 vascular sales.
Boston Scientific’s new Promus Element designs won FDA clearance in November 2011. The Natick, Mass.-based device giant announced Japanese approval for the system earlier this month.